Matt Henriksen

And I would just love to kind of hear your story because of how much Dexcom has changed in those 20, 22 years.

Your evolution in your career path from your first days at Dexcom until now your current CEO role.

That's great.

And so, you know, you talked about your seventh generation of the Dexcom device.

Why don't we just kind of take a quick step back and, you know, what is the CGM technology?

What is it designed to help patients monitor?

And, you know, how is that seventh generation evolved over the previous six?

Yeah.

And, you know, it's one of those things where every company is always trying to keep evolving because you have to keep evolving to keep up with the pace.

So how does that then, with your first year as CEO entering 2026, what are your key priorities kind of to keep that momentum going?

Interesting.

So let's just take a step back with the products themselves.

You talked about the seventh generation sensor that you have, but it kind of, in my opinion, it's almost a seven and a half generation because it's extended the wear time from a 10 day to a 15 day wear.

And you were just talking, the first generation was three days.

So you're doing a great job of being able to expand that to 15 days.

How do you convert those patients that are on the 10-day wear into a 15-day wear?

And then just on top of that too, is there patients on the sidelines who are waiting for that 15-day wear that are saying, okay, now that it's there, I can jump in and be able to use the product now?

Well, that's the thing.

And, you know, you guys talked in your pre-announcement that, you know, you have three and a half million users.

Even if you are cutting down the number of, you know, sensors per month from three to two, that's still a lot of sensors for a lot of patients per year.